Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- CMC +8.9%
Select chip related names showing strength:
- AMD +5.7%, NVDA +2.1%, MU +1.6%
Other news:
- TRVN +21.1% (announces FDA acceptance for review of New Drug Application for Olinvo injection )
- PTN +8.3% (FDA has notified Palatin that it may proceed with its clinical investigation of subcutaneous injection PL-8177)
- EGLT +6.8% (partners with OraPharma to co-promote SPRIX nasal spray)
- TTPH +6.6% (Tetraphase Pharmaceuticals submitted New Drug Application for intravenous eravacycline for the treatment of complicated intra-abdominal infections and promotes Larry Tsai, M.D. to Chief Medical Officer)
- ARDX +6.4% (completes T3MPO-3 safety extension study of Tenapanor for IBS-C )
- SGMO +5.4% (Sangamo Therapeutics and Pfizer (PFE) announce collaboration for development of zinc finger protein gene therapy for ALS )
- BB +4.1% (BlackBerry and Baidu (BIDU) announce they will collaborate to accelerate the deployment of connected and autonomous vehicle technology for automotive OEMs and suppliers worldwide)
- JCP +4% (following 10% move higher on the day)
- SSKN +4% (ticking higher after Sabby Management discloses increased active stake and letter expressing dissatisfaction with recent actions ), EEFT +3.9% (following MGI / BABA's Ant news)
- GLPG +3% (Galapagos NV updates progress with cystic fibrosis programs; started three new clinical studies, concluded the FLAMINGO study in CF patients, and expects to report patient data with a first proprietary investigational triple combination therapy in mid-2018; start of Phase 1 study triggers $10 mln milestone payment from AbbVie)
- PAH +3% (slightly higher after Elliott Associates discloses increased passive stake)
- KTOS +2.6% (awarded $14 mln Air Force contract - expected completion date Sept. 30, 2018)
Analyst comments:
- DKS +3.1% (upgraded to Outperform from Market Perform at Wells Fargo)
- ETFC +2.4% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- EXPE +2.3% (upgraded to Buy from Neutral at BofA/Merrill)
- ACM +2.1% (upgraded to Outperform from Neutral at Robert W. Baird)
- ORCL +1.6% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- CHTR +1.4% (upgraded to Buy from Neutral at Guggenheim)
- IBM +1.4% (upgraded to Outperform from Sector Perform at RBC Capital Mkts)
- UTX +1.4% (upgraded to Outperform from Sector Perform at RBC Capital Mkts)
- ULTA +1.3% (upgraded to Outperform from Market Perform at Wells Fargo)
- APO +1.2% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- ZNGA +1% (initiated with an Overweight at Consumer Edge Research)
- DIS +0.5% (upgraded to Buy from Neutral at Rosenblatt)